Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach ...

Some obese Americans on Medicare and Medicaid could get access to expensive weight loss drugs under a five-year experiment ...

If you suspect someone has been taking Ozempic, or Mounjaro, or Wegovy, or yet another fat jab, is it impolite to ask them?

Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural phenomenon.

State Medicaid programs already are allowed to offer GLP-1 drugs for weight loss, but only 13 state programs currently do so. Meanwhile, Medicare currently covers GLP-1 drugs for people with a ...

President Donald Trump's new European tariffs may spell bad news for Novo Nordisk, maker of Ozempic and Wegovy. As Axios ...

WAISTLINES are not the only things shrinking with the use of weight-loss jabs – supermarket bottom lines are too. Food sales ...

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

Gov. Phil Murphy's ideas to cut $100 million from the State Health Benefits Program include charging higher co-pays and ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...